Raymond James Maintains Outperform on Tandem Diabetes Care, Raises Price Target to $120
Raymond James analyst Jayson Bedford maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Outperform and raises the price target from $115 to $120.
SVB Leerink Maintains Market Perform on Tandem Diabetes Care, Raises Price Target to $123
SVB Leerink analyst Danielle Antalffy maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Market Perform and raises the price target from $102 to $123.
Tandem Diabetes Care Sees FY21 Sales $670M-$685M vs $637.16M Est.
2021 Annual Guidance Update
For the year ending December 31, 2021, the Company is updating its financial guidance as follows:
Sales are estimated to be in the range of $670
Tandem Diabetes Care Q2 EPS $0.06 Beats $(0.08) Estimate, Sales $172.10M Beat $143.63M Estimate
Tandem Diabetes Care (NASDAQ:TNDM) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.08) by 175 percent. This is a 113.33 percent increase over losses of $(0.45) per share
Earnings Scheduled For August 4, 2021
Companies Reporting Before The Bell
• UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.
Tandem Diabetes Sunday Highlighted Presentations Showing Improvements With Control-IQ Technology
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today presented positive real-world data from ongoing use of the t:slim X2™ insulin pump with Control-IQ®
Tandem Diabetes Care Announces Presentations Demonstrating ‘Immediate And Sustained Real-World Improvements With Control-IQ Technology’
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, announced data presented this week on real-world use of the t:slim X2™ insulin pump with Control-IQ™
Earnings Scheduled For May 5, 2021
Companies Reporting Before The Bell
• Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.